IPP Bureau
Novo Nordisk presents four new analyses on oral semaglutide 25 mg at ObesityWeek 2025
By IPP Bureau - November 06, 2025
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Zydus wellness reports 31% growth in net sales in Q2 FY26
By IPP Bureau - November 06, 2025
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
EazeBio and UC Santa Cruz partner to advance instrument-free diagnostic platform
By IPP Bureau - November 06, 2025
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Cupid bags largest share in South Africa’s 5-year National Condom Program
By IPP Bureau - November 06, 2025
Cupid has been allocated approximately 23.4 million units of female condoms per year
Ginkgo Bioworks and Bayer renew partnership to power the next wave of Ag Biologicals
By IPP Bureau - November 06, 2025
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
Sumitomo Pharma America unveils promising new leukemia and myelofibrosis data ahead of ASH 2025
By IPP Bureau - November 06, 2025
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
RedHill secures final $10.5M court judgment for enforcement
By IPP Bureau - November 06, 2025
RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment
Eli Lilly to invest $1.2 billion in Puerto Rico to boost U.S. oral medicine production
By IPP Bureau - November 06, 2025
J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial
By IPP Bureau - November 06, 2025
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
FDA approves UCB’s Kygevvi for rare genetic mitochondrial disease TK2 deficiency
By IPP Bureau - November 06, 2025
Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA
Bayer's finerenone approved in India for heart failure
By IPP Bureau - November 06, 2025
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Teva reports 11th consecutive quarter of growth
By IPP Bureau - November 06, 2025
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
IPP organises webinar on "Transforming Formulation R&D: Data, Digitalization and Beyond" on November 6, 2025
By IPP Bureau - November 05, 2025
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
Glenmark Pharmaceuticals USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq Single-Dose Vial
By IPP Bureau - November 05, 2025
Glenmark will begin distribution in November 2025
Zydus receives FDA’s tentative approval for Budesonide delayedrelease capsules, 4 mg
By IPP Bureau - November 05, 2025
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
